Paul V. O’Donnell

10.1k total citations
121 papers, 4.4k citations indexed

About

Paul V. O’Donnell is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, Paul V. O’Donnell has authored 121 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Hematology, 32 papers in Immunology and 27 papers in Oncology. Recurrent topics in Paul V. O’Donnell's work include Hematopoietic Stem Cell Transplantation (68 papers), Immune Cell Function and Interaction (21 papers) and Acute Lymphoblastic Leukemia research (21 papers). Paul V. O’Donnell is often cited by papers focused on Hematopoietic Stem Cell Transplantation (68 papers), Immune Cell Function and Interaction (21 papers) and Acute Lymphoblastic Leukemia research (21 papers). Paul V. O’Donnell collaborates with scholars based in United States, United Kingdom and India. Paul V. O’Donnell's co-authors include Ephraim J. Fuchs, Leo Luznik, Richard J. Jones, Elisabeth Stockert, Lloyd J. Old, Claudio G. Brunstein, Richard F. Ambinder, Mary S. Leffell, Mary Eapen and Jeannine S. McCune and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Paul V. O’Donnell

117 papers receiving 4.1k citations

Peers

Countries citing papers authored by Paul V. O’Donnell

Since Specialization

Citations

This map shows the geographic impact of Paul V. O’Donnell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul V. O’Donnell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul V. O’Donnell more than expected).

Fields of papers citing papers by Paul V. O’Donnell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul V. O’Donnell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul V. O’Donnell. The network helps show where Paul V. O’Donnell may publish in the future.

Co-authorship network of co-authors of Paul V. O’Donnell

This figure shows the co-authorship network connecting the top 25 collaborators of Paul V. O’Donnell. A scholar is included among the top collaborators of Paul V. O’Donnell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul V. O’Donnell. Paul V. O’Donnell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II Study of Peri- and Post-Transplant Ruxolitinib for Patients With Myelofibrosis Receiving Allogeneic Hematopoietic Cell Transplantation 2025 ·Gabriela Hobbs, Haesook T. Kim, (unknown), Mark A. Schroeder, Roni Tamari, Sarah Wall, (unknown), Areej El‐Jawahri, Matthew J. Frigault, Steven L. McAfee, Richard Newcomb, Paul V. O’Donnell, Thomas R. Spitzer, Jonas S. Jutzi, Yi‐Bin Chen, Zachariah DeFilipp	1
2	Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT 2025 ·Blood ·Zachariah DeFilipp, Haesook T. Kim, (unknown), (unknown), (unknown), Meghan White, Bhagirathbhai Dholaria, Mark A. Schroeder, Sumithira Vasu, Sameem Abedin, Joo‐Ho Chung, Areej El‐Jawahri, Matthew J. Frigault, Steven L. McAfee, Richard Newcomb, Paul V. O’Donnell, Thomas R. Spitzer, Yi‐Bin Chen, Gabriela Hobbs	5
3	Cost-Effectiveness of Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Bone Marrow Transplantation: Evidence from BMT CTN 1101 2023 ·Transplantation and Cellular Therapy ·Scott D. Ramsey, Aasthaa Bansal, (unknown), Paul V. O’Donnell, Ephraim J. Fuchs, Claudio G. Brunstein, Mary Eapen, Viengneesee Thao, Joshua A. Roth, Lotte Steuten	4
4	Health-Related Quality of Life in Double Umbilical Cord Blood versus Haploidentical Marrow Transplantation: A Quality of Life Analysis Report of BMT CTN 1101 2023 ·Transplantation and Cellular Therapy ·Najla El Jurdi, Michael J. Martens, Claudio G. Brunstein, Paul V. O’Donnell, Stephanie J. Lee, Anita D’Souza, Brent R. Logan, Sanghee Hong, Anurag K. Singh, Karamjeet Sandhu, Roman M. Shapiro, Mary M. Horowitz, Betty K. Hamilton	3
5	The development of post-transplant cyclophosphamide: Half a century of translational team science 2022 ·Blood Reviews ·Paul V. O’Donnell, Richard J. Jones	10
6	Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes 2021 ·Transplantation and Cellular Therapy ·Paul V. O’Donnell, Claudio G. Brunstein, Ephraim J. Fuchs, Mei‐Jie Zhang, (unknown), Joseph H. Antin, Eric Leifer, Hany Elmariah, Michael R. Grunwald, Hamza Hashmi, Mary M. Horowitz, John Magenau, Navneet S. Majhail, Filippo Milano, Lawrence E. Morris, Andrew R. Rezvani, Joseph P. McGuirk, Richard J. Jones, Mary Eapen	10
7	Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin 2021 ·Bone Marrow Transplantation ·Albert C. Yeh, Paul V. O’Donnell, Gary Schoch, Paul J. Martin, (unknown), Jeannine S. McCune, Jason P. Cooper, Kris Doney, Mary E.D. Flowers, Mohamed L. Sorror, Frederick R. Appelbaum, Barry E. Storer, Ted Gooley, H. Joachim Deeg	4
8	MRI features of low-grade and high-grade chondrosarcoma in enchondromatosis 2021 ·Skeletal Radiology ·(unknown), (unknown), (unknown), Paul V. O’Donnell, Asif Saifuddin	6
9	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial 2020 ·Blood ·Ephraim J. Fuchs, Paul V. O’Donnell, Mary Eapen, Brent R. Logan, Joseph H. Antin, Peter Dawson, Steven M. Devine, Mary M. Horowitz, Mitchell E. Horwitz, Chatchada Karanes, Eric Leifer, John Magenau, Joseph P. McGuirk, Lawrence E. Morris, Andrew R. Rezvani, Richard J. Jones, Claudio G. Brunstein	106
10	EWSR1-SMAD3 fibroblastic tumour of bone: expanding the clinical spectrum 2020 ·Skeletal Radiology ·(unknown), Adrienne M. Flanagan, Roberto Tirabosco, Paul V. O’Donnell, Fernanda Amary	6
11	Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure 2019 ·Blood ·Yi‐Bin Chen, Nahel Elias, Eliot Heher, Jeannine S. McCune, Kerry Collier, Shuli Li, Candice Del Rio, Areej El‐Jawahri, Winfred W. Williams, Nina Tolkoff-Rubin, Jay A. Fishman, Steven L. McAfee, Bimalangshu R. Dey, Zachariah DeFilipp, Paul V. O’Donnell, A. Benedict Cosimi, David H. Sachs, Tatsuo Kawai, Thomas R. Spitzer	19
12	Posttransplant cyclophosphamide in allogeneic bone marrow transplantation for the treatment of nonmalignant hematological diseases 2019 ·Bone Marrow Transplantation ·Mark B. Leick, Bradley D. Hunter, Zachariah DeFilipp, Bimalangshu R. Dey, Areej El‐Jawahri, Matthew J. Frigault, Steven L. McAfee, Thomas R. Spitzer, Paul V. O’Donnell, Yi‐Bin Chen	6
13	CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study 2017 ·Cytotherapy ·Sarita Rani Jaiswal, (unknown), (unknown), Aditi Chakrabarti, (unknown), (unknown), (unknown), (unknown), Paul V. O’Donnell, Suparno Chakrabarti	51
14	Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies 2014 ·Biology of Blood and Marrow Transplantation ·Mary Eapen, Paul V. O’Donnell, Claudio G. Brunstein, Juan Wu, (unknown), Adam Mendizabal, Ephraim J. Fuchs	28
15	The Contribution of Malglycemia to Mortality among Allogeneic Hematopoietic Cell Transplant Recipients 2009 ·Biology of Blood and Marrow Transplantation ·Marilyn J. Hammer, Corey Casper, Ted Gooley, Paul V. O’Donnell, Michael Boeckh, Irl B. Hirsch	70
16	Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab 2007 ·Clinical Cancer Research ·Jesús G. Berdeja, Allan D. Hess, David Lucas, Paul V. O’Donnell, Richard F. Ambinder, Louis F. Diehl, (unknown), Susan E Newton, Ian W. Flinn	38
17	Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide 2002 ·Biology of Blood and Marrow Transplantation ·Paul V. O’Donnell, Leo Luznik, Richard J. Jones, G. B. Vogelsang, Mary S. Leffell, Mitch A. Phelps, (unknown), Kenneth H. Cowan, S Piantadosi, Ephraim J. Fuchs	324
18	Dimethylsulfoxide-Induced Alterations in the Growth Properties and Protein Composition of in vitro-Propagated Murine Hepatoma Cells 1982 ·Oncology ·Paul J. Higgins, Paul V. O’Donnell	11
19	A cell surface antigen of the mouse related to xenotropic MuLv defined by naturally occurring antibody and monoclonal antibody. Relation to Gix G(rada1), G(aksl2) systems of MuLV-related antigens. 1981 ·The Journal of Experimental Medicine ·Yuuki Obata, Elisabeth Stockert, Albert B. DeLeo, Paul V. O’Donnell, Harry W. Snyder, Lloyd J. Old	17
20	G(RADA1): a new cell surface antigen of mouse leukemia defined by naturally occurring antibody and its relationship to murine leukemia virus. 1978 ·The Journal of Experimental Medicine ·Yuuki Obata, Elisabeth Stockert, Paul V. O’Donnell, Sachie Okubo, Harry W. Snyder, Lloyd J. Old	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact